American Century Companies Inc. Buys 32,240 Shares of Teladoc Health, Inc. (NYSE:TDOC)

American Century Companies Inc. boosted its position in Teladoc Health, Inc. (NYSE:TDOC) by 31.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 136,351 shares of the health services provider’s stock after acquiring an additional 32,240 shares during the quarter. American Century Companies Inc.’s holdings in Teladoc Health were worth $1,334,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Parallel Advisors LLC increased its position in Teladoc Health by 14.6% in the 4th quarter. Parallel Advisors LLC now owns 4,038 shares of the health services provider’s stock valued at $87,000 after acquiring an additional 515 shares during the period. Ignite Planners LLC lifted its holdings in Teladoc Health by 6.9% during the 1st quarter. Ignite Planners LLC now owns 13,307 shares of the health services provider’s stock worth $198,000 after buying an additional 857 shares during the period. ICA Group Wealth Management LLC bought a new stake in shares of Teladoc Health in the 4th quarter valued at about $28,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Teladoc Health by 2.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 65,588 shares of the health services provider’s stock valued at $641,000 after buying an additional 1,352 shares during the period. Finally, Covestor Ltd raised its position in shares of Teladoc Health by 58.1% during the first quarter. Covestor Ltd now owns 3,817 shares of the health services provider’s stock worth $57,000 after acquiring an additional 1,403 shares during the last quarter. Institutional investors and hedge funds own 76.82% of the company’s stock.

Teladoc Health Price Performance

Teladoc Health stock opened at $8.46 on Monday. The firm has a market capitalization of $1.43 billion, a PE ratio of -6.00 and a beta of 0.90. Teladoc Health, Inc. has a 12-month low of $6.76 and a 12-month high of $22.54. The firm has a 50-day moving average price of $7.93 and a 200-day moving average price of $10.62. The company has a current ratio of 1.66, a quick ratio of 1.62 and a debt-to-equity ratio of 0.66.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings results on Wednesday, July 31st. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.08. Teladoc Health had a negative return on equity of 10.25% and a negative net margin of 38.54%. The firm had revenue of $642.44 million during the quarter, compared to analyst estimates of $649.34 million. As a group, equities research analysts forecast that Teladoc Health, Inc. will post -1.18 EPS for the current year.

Insider Buying and Selling at Teladoc Health

In other Teladoc Health news, insider Vidya Raman-Tangella sold 3,857 shares of the firm’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $8.14, for a total value of $31,395.98. Following the completion of the sale, the insider now owns 33,667 shares of the company’s stock, valued at $274,049.38. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other Teladoc Health news, CEO Laizer Kornwasser sold 10,879 shares of the stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $8.14, for a total transaction of $88,555.06. Following the completion of the transaction, the chief executive officer now owns 99,929 shares of the company’s stock, valued at $813,422.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Vidya Raman-Tangella sold 3,857 shares of the company’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $8.14, for a total transaction of $31,395.98. Following the sale, the insider now directly owns 33,667 shares of the company’s stock, valued at approximately $274,049.38. The disclosure for this sale can be found here. Insiders have sold 57,819 shares of company stock worth $442,204 over the last quarter. Insiders own 0.95% of the company’s stock.

Analysts Set New Price Targets

TDOC has been the topic of several recent analyst reports. Oppenheimer dropped their target price on shares of Teladoc Health from $21.00 to $17.00 and set an “outperform” rating on the stock in a report on Thursday, August 1st. JPMorgan Chase & Co. lowered their price objective on shares of Teladoc Health from $16.00 to $9.00 and set a “neutral” rating for the company in a research note on Monday, August 26th. Jefferies Financial Group raised their price target on shares of Teladoc Health from $8.00 to $10.00 and gave the stock a “hold” rating in a report on Tuesday, September 17th. Canaccord Genuity Group cut their price objective on shares of Teladoc Health from $25.00 to $17.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Finally, Evercore ISI decreased their target price on Teladoc Health from $14.00 to $10.00 and set an “in-line” rating for the company in a research report on Tuesday, July 9th. Fifteen equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Teladoc Health presently has a consensus rating of “Hold” and a consensus target price of $12.31.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.